Research and Strategy

Braincure Biotech’s Research and Development strategy is to utilize its ImmunoTX (immunotherapeutics) and Smolecs (small molecules) technology platforms to generate a broad array of innovative products for diseases, such as Alzheimer’s that involve misfolded proteins. The company’s pipeline includes antibodies, vaccines and small molecules for therapeutic use as well as small molecules and antibodies for both imaging and in vitro diagnostic products.

Conventional technologies are not widely applicable to the development of diseases that involve misfolded proteins for the following two reasons:

  • Even when misfolded, these proteins are still recognized by the human immune system as “self” and therefore do not elicit immune responses and

  • Since the differences between the “good” and “bad” versions of a protein are solely related to their conformations, creating a therapeutic that differentiates between them is a challenge. Moreover, a conventional therapeutic that is active against both the normal and misfolded versions of a protein increases the risk of toxicity and also decreases the amount of drug active against the “bad “protein conformation.

The ImmunoTX and Smolecs technologies, however, produce molecules that are specific only to the misfolded forms of proteins and bind to them with high affinity. This makes Braincure Biotech’s products potent as therapeutics and accurate as diagnostics.

Neurodegenerative disease is a large therapeutic area whose pathology is related to misfolded proteins. Of the many devastating illnesses in this category, perhaps none inflicts as much damage to as many people worldwide as Alzheimer’s disease. Braincure Biotech is developing a comprehensive array of products that attack the disease on almost all fronts. Although the underlying cause of the disease is not known, misfolded versions of two proteins, beta amyloid (Abeta) and Tau, form aggregates that kill the brain cells of Alzheimer’s patients. Braincure Biotech used its ImmunoTX and Smolecs platforms to design the following: a therapeutic antibody specific to misfolded Abeta, an active vaccine against misfolded Abeta, a small molecule that prevents aggregation of Abeta, a therapeutic antibody against misfolded and hyperphosphorylated Tau protein, an active vaccine against misfolded Tau protein and a small molecule that prevents Tau aggregation.

In addition, Braincure Biotech’s Research and Development strategy involves leveraging its initial work in Alzheimer’s disease to create products for a variety of other diseases that involve either misfolded Abeta (Glaucoma), or misfolded Tau (the neurodegenerative tauopathies), or misfolded versions of other proteins involved in Parkinson’s disease, Amyotrophic Lateral Sclerosis and Huntington’s disease.